Verseon Corporation develops and applies proprietary artificial intelligence and technology platforms for drug discovery and development. The company develops pharmaceuticals and consumer healthspan products, providing a technology platform that combines physics-based molecular modeling and artificial intelligence for de novo molecular design and drug discovery. Its AI technology, VersaiTM, is used to improve accuracy in drug discovery, particularly in situations with limited data, and offers real-time explainable AI and accelerated model training. The company partners with other organizations to enhance drug development, drug-candidate selection, and clinical-trial design, and holds patents for drug candidates targeting cardiovascular conditions. It offers solutions for the prevention, delay, and treatment of diseases and age-related degeneration, and serves clients in the pharmaceutical industry and academia. The company was founded in 2002 and is based in Fremont, California.